Molecular features of circulating B-cell clonal expansions at different times of therapeutic protocols
| Protocol timing . | Therapeutic schedule . | |||||
|---|---|---|---|---|---|---|
| PIRR, n = 22 . | Peg-IFN-α/RBV, n = 15 . | |||||
| Monoclonal . | Oligoclonal . | Polyclonal . | Monoclonal . | Oligoclonal . | Polyclonal . | |
| Start | 10 (45.5) | 12 (54.5) | 0 | 6 (40) | 7 (46.7) | 2 (13.3) |
| End of therapy | 9 (41) | 1 (4.5) | 12 (54.5) | 6 (40) | 3 (20) | 6 (40) |
| End of follow-up | 9 (41) | 3 (13.5) | 10 (45.5) | 6 (40) | 7 (46.7) | 2 (13.3) |
| Protocol timing . | Therapeutic schedule . | |||||
|---|---|---|---|---|---|---|
| PIRR, n = 22 . | Peg-IFN-α/RBV, n = 15 . | |||||
| Monoclonal . | Oligoclonal . | Polyclonal . | Monoclonal . | Oligoclonal . | Polyclonal . | |
| Start | 10 (45.5) | 12 (54.5) | 0 | 6 (40) | 7 (46.7) | 2 (13.3) |
| End of therapy | 9 (41) | 1 (4.5) | 12 (54.5) | 6 (40) | 3 (20) | 6 (40) |
| End of follow-up | 9 (41) | 3 (13.5) | 10 (45.5) | 6 (40) | 7 (46.7) | 2 (13.3) |
Molecular features data are reported as number (%).